Several preclinical and clinical studies suggested that IL6R inhibitors, such as Tocilizumab, Sarilumab, and Olamkicept, can be effective in some cancer type including ovarian, pancreatic, breast cancer, and B cell chronic lymphocytic leukemia [7]. Here, IL6R is linked to breast carcinoma.